Durvalumab after Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer.
Ying ChengDavid R SpigelByoung Chul ChoKonstantin K LaktionovJian FangYuanbin ChenYoshitaka ZenkeKi Hyeong LeeQiming WangAlejandro NavarroReyes BernabeEva Lotte BuchmeierJohn Wen-Cheng ChangYoshimasa ShiraishiSema Sezgin GoksuAndrzej BadzioAnhui ShiDavey B DanielNguyen Thi Thai HoaMilada ZemanovaHelen MannHema GowdaHaiyi JiangSuresh Senannull nullPublished in: The New England journal of medicine (2024)
Adjuvant therapy with durvalumab led to significantly longer overall survival and progression-free survival than placebo among patients with limited-stage small-cell lung cancer. (Funded by AstraZeneca; ADRIATIC ClinicalTrials.gov number, NCT03703297.).